Log in to search using one of your social media accounts:

 

Startup aims to disrupt asthma, COPD space with digital inhaler

Formed just two years ago, pharma startup Pneuma Respiratory is developing a digital inhaler that it touts as the first of its kind. The company is looking to bring its technology to the more than 40 million people who suffer from asthma or chronic obstructive pulmonary disease in the U.S. They’re stepping into a highly competitive market, largely dominated by companies like GlaxoSmithKline (NYSE:GSK) and Merck (NYSE:MRK). Get the full story at our sister site, Drug Delivery Business News. The post Startup aims to disrupt asthma, COPD space with digital inhaler appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations mHealth (Mobile Health) Pharma Pharmaceuticals Respiratory GlaxoSmithKline plc Merck Pfizer pneumarespiratory Source Type: news

Related Links:

Objective: We use a single-alveolar-compartment model to describe the partial pressure of carbon dioxide in exhaled breath, as recorded in time-based capnography. Respiratory parameters are estimated using this model, and then related to the clinical status of patients with obstructive lung disease. Methods: Given appropriate assumptions, we derive an analytical solution of the model, describing the exhalation segment of the capnogram. This solution is parametrized by alveolar CO2 concentration, dead-space fraction, and the time constant associated with exhalation. These quantities are estimated from individual capnogram d...
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Authors: Stolzenburg LR, Harris A Abstract Chronic respiratory diseases encompass a group of diverse conditions affecting the airways, which all impair lung function over time. They include cystic fibrosis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and asthma, which together affect hundreds of millions of people worldwide. MicroRNAs (miRNAs), a class of small non-coding RNAs involved in post-transcriptional gene repression, are now recognized as major regulators in the development and progression of chronic lung disease. Alterations in miRNA abundance occur in lung tissue, inflammatory c...
Source: Biological Chemistry - Category: Chemistry Tags: Biol Chem Source Type: research
ConclusionAs an aggregate of several clinical parameters, this index serves as a cumulative measure of physiological dysregulation and could be utilized as a prognostic indicator of life expectancy and morbidity risk.
Source: American Journal of Industrial Medicine - Category: Occupational Health Authors: Tags: RESEARCH ARTICLE Source Type: research
Condition:   Asthma Interventions:   Other: Telephonic interviews;   Other: E-RS: COPD;   Other: Supplemental asthma items;   Other: Daily diary;   Other: Sociodemographic questionnaire;   Other: Clinical questionnaire Sponsors:   GlaxoSmithKline;   Evidera Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Propeller Health said today it inked a strategic partnership deal with Express Scripts (NSDQ:ESRX) to provide Propeller’s digital solutions to Express Script members. Through the deal, St. Louis-based Express Script members will be able to use inhaler sensors and connected mobile applications to manage their asthma or chronic obstructive pulmonary disease. The companies touted it as the largest respiratory digital health deployment with a pharmacy manager to date. Read the whole story on our sister site, Drug Delivery Business The post Propeller Health, Express Scripts ink smart inhaler sensor deal app...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Drug-Device Combinations Patient Monitoring Respiratory Express Scripts Propeller Health Source Type: news
-- Smoke from a nearby wildfire threatens anyone, but poses even more of a threat to people with asthma, COPD, heart disease or diabetes, the American Lung Association says. The group suggests what to do if a wildfire burns near you: Stay inside,...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Conclusions These findings could help inform the evaluation of interventions to prevent and manage noncommunicable chronic diseases and their potential to control costs among the vulnerable Medicaid population.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Authors: Renaud-Picard B, Toussaint J, Leclercq A, Reeb J, Kessler L, Toti F, Kessler R Abstract Microparticles (MP) are plasmic membrane fragments released from cells after physiological stimulation or stress conditions like inflammation or infection. Their production is correlated to the rate of cell apoptosis. All types of cells can produce MP but they are produced mainly by platelets, endothelial cells, and leukocytes. They carry many bio-active molecules on their surface, specific to the parental cell, giving them the ability to be biomarkers and bio-effectors. MP are present in circulating blood, tissues and ...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Authors: Hoy RF, Brims F Abstract Occupational exposures are an important determinant of respiratory health. International estimates note that about 15% of adult-onset asthma, 15% of chronic obstructive pulmonary disease and 10-30% of lung cancer may be attributable to hazardous occupational exposures. One-quarter of working asthmatics either have had their asthma caused by work or adversely affected by workplace conditions. Recently, cases of historical occupational lung diseases have been noted to occur with new exposures, such as cases of silicosis in workers fabricating kitchen benchtops from artificial stone p...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Pneuma Respiratory, a young company out of Boone, North Carolina, has announced that it developed a digital soft mist inhaler that can be set to deliver different size drug particles to the lungs, and that works with a variety of medications including large-molecule compounds. The company’s droplet ejector technology generates whichever size droplets are preferred and intelligently injects the soft mist into the air stream as the patient breathes in from the inhaler. Having different size droplets may significantly help improve a drug’s effectiveness, as the droplet’s size plays a role in determining whic...
Source: Medgadget - Category: Medical Devices Authors: Tags: Medicine Pediatrics Thoracic Surgery Source Type: blogs
More News: Asthma | Chronic Obstructive Pulmonary | Merck | Pfizer | Pharmaceuticals | Respiratory Medicine